Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
17/06/2024 | 14:03 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
14/06/2024 | 13:21 | IH Market News | Adobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and More | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
04/06/2024 | 22:05 | Business Wire | Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
01/06/2024 | 20:25 | Business Wire | New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
01/06/2024 | 20:20 | Business Wire | Teva Presents First Real-World Data from the IMPACT-TD Registry Study at Psych Congress Elevate 2024 | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
30/05/2024 | 00:38 | Business Wire | Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 mg/day) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
21/05/2024 | 02:25 | GlobeNewswire Inc. | Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S. | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
15/05/2024 | 14:30 | Edgar (US Regulatory) | Form 8-K - Current report | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
15/05/2024 | 14:15 | Business Wire | Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
09/05/2024 | 13:53 | IH Market News | Bain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More News | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
08/05/2024 | 13:00 | Business Wire | Teva Reports First Quarter 2024 Financial Results and Reaffirms 2024 Financial Outlook | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
08/05/2024 | 12:30 | Business Wire | Teva and Medincell Announce Positive Phase 3 Efficacy Results from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable in Adults with Schizophrenia | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
03/05/2024 | 00:30 | Business Wire | Teva to Present at the 2024 Bank of America Healthcare Conference | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
02/05/2024 | 14:30 | Business Wire | Teva’s 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious Targets | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
30/04/2024 | 10:00 | GlobeNewswire Inc. | U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
16/04/2024 | 23:43 | Business Wire | Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab) | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
16/04/2024 | 14:00 | Business Wire | Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
11/04/2024 | 14:30 | Business Wire | Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
09/04/2024 | 22:30 | Business Wire | Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024 | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
06/04/2024 | 19:00 | Business Wire | New Pharmacokinetic Modeling Data Presented by Teva Simulates Clinical Profiles of Schizophrenia Patients Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension at SIRS 2024 | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
04/04/2024 | 14:30 | Business Wire | Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
01/04/2024 | 14:30 | Business Wire | Clinical Collaboration Agreement between Teva and Launch Therapeutics to Accelerate Development of Dual-Action Asthma Rescue Inhaler (ICS-SABA/TEV-’248) Respiratory Program; Teva and Abingworth Enter Strategic Development Funding Agreement | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
05/03/2024 | 22:43 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
26/02/2024 | 13:00 | Business Wire | Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
24/02/2024 | 02:15 | GlobeNewswire Inc. | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
24/02/2024 | 02:15 | Business Wire | Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira® | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
20/02/2024 | 14:30 | Business Wire | Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
13/02/2024 | 15:05 | IH Market News | Hotter-Than-Expected Inflation Data Likely To Weigh On Wall Street | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
12/02/2024 | 23:03 | IH Market News | Dow Reaches New Record Closing High But Nasdaq, S&P 500 Give Back Ground | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |
12/02/2024 | 15:13 | IH Market News | Teva Pharmaceutical, Urban Outfitters Upgraded | NYSE:TEVA | Teva Pharmaceutical Industries Ltd |